Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VIGORous Debate Continues In NEJM Over Propriety Of Merck’s Vioxx Study

Executive Summary

Merck's Vioxx VIGOR trial results do not need to be corrected, authors of the study assert in letters to the editors of the New England Journal of Medicine Feb. 22

You may also be interested in...

Medical Journals Need Taste Of Their Own Medicine, FDA’s Gottlieb Says

Medical journals need to take measures to expedite providing up-to-date information to physicians, FDA Deputy Commissioner for Scientific & Regulatory Affairs Scott Gottlieb said

Merck Will Need VIGOR To Defend Vioxx Data Following NEJM Claims

The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication

Merck After Vioxx: No Merger, But No Big Near-Term Launches

Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts